RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 Prospects for siRNAs, shRNAs and ddRNAi Approaches

Jul 22, 2015, 09:00 ET from Visiongain

LONDON, July 22, 2015 /PRNewswire/ --

RNAi therapies - new study showing you trends, R&D progress, and predicted revenues
When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 174-page report provides 95 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
Joseph Payne, CEO, Arcturus Therapeutics
J. Michael French, President and CEO, Marina Biotech

See revenue forecasts for the most promising products in development
How will leading RNAi therapies perform to 2025 at world level? Our study forecasts sales of 11 products, including:
• ALN-TTR02 (patisiran)
• Vigil immunotherapy
• ALN-TTRsc (revusiran)
• ARC-520
• Atu027
• PF-655
• QPI-1002
• RXI-109
• siG12D-LODER
• SPC3649 (miravirsen)
• SYL040012

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 4 regional markets plus the Rest of the World to 2025:
• US
• EU5
Latin America
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that the US, in particular, will achieve high revenue growth to 2025. Developments worldwide in biotechnology infrastructure and RNAi therapy development will influence the market.

Leading companies and potential for market growth
Overall world revenue for RNAi therapies will reach $391m in 2018, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and high unmet medical needs in many markets will increase sales to 2025.

Our work shows you what organisations hold greatest potential. See visiongain's analysis of 11 leading companies, including these:
• Alnylam Pharmaceuticals
• Arrowhead Research
• Benitec Biopharma
• Gradalis Incorporated
• Quark Pharmaceuticals
• Roche Innovation Center Copenhagen (formerly Santaris Pharma)
• RXi Pharmaceuticals
• Silence Therapeutics
• Silenseed
• Sylentis
• Tekmira Pharmaceuticals.

A company profile gives you the following information where available:
• Historical revenues from 2010 to 2014
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas and technologies:
• Small interfering RNA (siRNA) therapies
• Short hairpin RNA (shRNA) therapies
• DNA-directed RNAi (ddRNAi) therapies
• Delivery technologies such as lipid nanoparticles and viral vectors
• Other progress in RNAi therapy development.

RNAi therapy R&D is strong in siRNA-based therapies. Novel compounds and new delivery vectors with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the RNAi therapies industry?
Our new report discusses issues and events affecting the RNAi therapies market. You will find discussions, including qualitative analyses:
• Approval of other oligonucleotide products indicates a path to market acceptance
• Challenges exist with delivery of current RNAi therapies
• Big Pharma is investing in RNAi therapy developers
• Alternative approaches to gene silencing are advancing rapidly

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 report helps you
In summary, our 174-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the world RNAi therapies market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for the leading 5 regional markets - US, EU5, Asia-Pacific, Latin America and Rest of the World
• Predicted revenues of 11 leading drugs to 2025 - see potentials of top products
• Assessment of 11 leading companies - hear about products, results and strategies including pipeline analysis and recent developments
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the RNAi therapies market and leading companies. You find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Companies Listed
Acuity Pharmaceuticals (now OPKO Health)
Aegera Therapeutics
Agilent Technologies
Alcon (subsidiary of Novartis)
Allele Biotechnology
Altogen Labs
AmpliPhi Biosciences
Antisense Therapeutics
Aptose Biosciences
Arcturus Therapeutics
ArmaGen Technologies
Arrowhead Research
Ascletis Pharmaceuticals
Atugen AG (acquired by Silence Therapeutics)
Avecia OligoMedicines
Benitec Biopharma
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
Biomics Biotechnology
BioSpring GmbH
Blueberry Therapeutics
Bristol-Myers Squibb
Calando Pharmaceuticals (subsidiary of Arrowhead)
CRISPR Therapeutics
Cubist Pharmaceuticals (acquired by Merck)
Dainippon Sumitomo
Dharmacon RNAi Technologies (part of GE Healthcare)
DuPont Pharmaceuticals
Eli Lilly
Entelos, Inc
Enzo Therapeutics
Enzon Pharmaceuticals
Eurofins MWG-Biotech
Express Scripts
Eyetech Pharmaceuticals
GE Healthcare
Gene Link
Gene Signal
GeneCare Research Institute
Genzyme (part of Sanofi)
Gilead Sciences
Girindus America (part of Solvay Group)
Gradalis Incorporated
Halo-Bio RNAi Therapeutics
Integrated DNA Technologies
Intradigm Corporation (merged into Silence Therapeutics)
Isarna Therapeutics
Isis Pharmaceuticals
Kunshan RiboQuark Pharmaceutical Technology (RiboQuark)
Kyowa Hakko Kirin
Life Technologies
Life Technologies (part of Thermo Fisher Scientific)
Marina Biotech
MedImmune (subsidiary of AstraZeneca)
Merck & Co. (Merck)
Mirna Therapeutics
Moderna Therapeutics
Nitto Denko
Noxxon Pharma
Oligoengine (division of Halo-Bio RNAi Therapeutics)
Omnia Biologics
OnCore Biopharma (merged into Tekmira)
OPKO Health
PharmaMar (subsidiary of Zeltia)
Pharmasset (part of Gilead Sciences)
ProNAi Therapeutics
Protiva Biotherapeutics
Quark Pharmaceuticals
Regulus Therapeutics
Ribopharma AG (now part of Alnylam)
Roche Innovation Center Copenhagen (part of Roche)
RXi Pharmaceuticals
SABiosciences (part of Qiagen)
Samyang Corporation
Santaris Pharma (acquired by Roche)
Sarepta Therapeutics
Silence Therapeutics
Sirna Therapeutics (assets acquired by Alnylam)
Solvay Group
Suzhou Ribo Life Science
Sylentis (subsidiary of Zeltia)
Synteract Inc.
Tacere Therapeutics (acquired by Benitec)
The Medicines Company (MDCO)
Thermo Fisher Scientific
Traversa Therapeutics
Zeltia Group

Other Organisations Mentioned in this Report

American Cancer Society (ACS)
American Society of Clinical Oncology (ASCO)
American Society of Gene and Cellular Therapy (ASGCT)
Brazilian Industrial Biotech Association
Brigham Young University
Carnegie Institution for Science
Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia)
European Medicines Agency (EMA)
European Patent Office (EPO)
Georgetown University
Hannover Medical School
Kunshan RNAi Institute
Mary Crowley Cancer Research Centre
Max Planck Institute
MD Anderson Cancer Center
Ministry of Science and Technology (India)
National Institute for Health and Care Excellence (NICE) (UK)
National Institutes of Health (NIH) (US)
Ohio State University (OSU)
Pachyonychia Congenita Project
United States Food and Drug Administration (FDA)
University of Bayreuth
University of Calgary
University of Helsinki
University of Massachusetts Medical School
University of Oxford
University of Pittsburgh
US Department of Defense
Wellcome Trust
World Health Organization (WHO)

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
Or click on https://goo.gl/JnW7UK

SOURCE Visiongain